Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Loser

Alexion Pharmaceuticals ( ALXN) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.5%. By the end of trading, Alexion Pharmaceuticals fell 82 cents (-0.8%) to $100.43 on light volume. Throughout the day, 1.3 million shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of two million shares. The stock ranged in price between $99.59-$102.17 after having opened the day at $101.03 as compared to the previous trading day's close of $101.25. Other company's within the Drugs industry that declined today were: K-V Pharmaceutical Company ( KV.B), down 16.9%, Amyris ( AMRS), down 12%, K-V Pharmaceutical Company ( KV.A), down 10%, and Savient Pharmaceuticals ( SVNT), down 9.6%.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Alexion Pharmaceuticals has a market cap of $19.34 billion and is part of the health care sector. The company has a P/E ratio of 103.4, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 44.6% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Telik ( TELK), up 36.8%, Palatin Technologies ( PTN), up 16.6%, Rexahn Pharmaceuticals ( RNN), up 15.4%, and Questcor Pharmaceuticals ( QCOR), up 14.8%, were all gainers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Tiffany & Co. Sees a Strong Market in Asia

Tiffany & Co. Sees a Strong Market in Asia

Stocks Finish Higher After Release of Fed Minutes

Stocks Finish Higher After Release of Fed Minutes

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation